| Literature DB >> 27107130 |
In-Jeong Cho1, Hyuk-Jae Chang2, Iksung Cho1, Ran Heo1, Sang-Eun Lee1, Chi Young Shim1, Geu-Ru Hong1, Namsik Chung1.
Abstract
BACKGROUND: The structure of the aorta is considered to influence exercise systolic blood pressure (SBP) response, which, in turn, might impact upon adverse outcomes. The current study sought to investigate the relationship of aortic calcification and exercise SBP with adverse outcomes among elderly individuals. METHODS ANDEntities:
Keywords: aorta; blood pressure; calcification; exercise
Mesh:
Substances:
Year: 2016 PMID: 27107130 PMCID: PMC4859288 DOI: 10.1161/JAHA.115.003131
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics
| Variable | Participants (n=702) |
|---|---|
| Baseline characteristics | |
| Age, y | 69±4 |
| Men, n (%) | 298 (42) |
| Diabetes, n (%) | 125 (18) |
| Smoking, n (%) | 95 (14) |
| Dyslipidemia, n (%) | 348 (50) |
| Hypertension, n (%) | 392 (56) |
| Medications n (%) | |
| Beta‐blocker | 269 (38) |
| Calcium‐channel blocker | 249 (35) |
| ACEi/ARB | 177 (25) |
| BMI, kg/m2 | 24.5±2.7 |
| Total cholesterol/HDL ratio | 3.7±0.9 |
| Resting systolic BP, mm Hg | 125.0±15.7 |
| Resting diastolic BP, mm Hg | 76.5±9.2 |
| Resting PP, mm Hg | 48.2±14.6 |
| Resting heart rate, bpm | 57.9±7.4 |
| CT variables | |
| CACS, mm3 | 4 (0–56) |
| log(CACS+1) | 2.1±2.2 |
| TACS, mm3 | 442 (125–1235) |
| log(TACS+1) | 5.9±1.9 |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor antagonist; BMI, body mass index; BP, blood pressure; CACS, coronary artery calcium score; CT, computed tomography; HDL, high‐density lipoprotein; PP, pulse pressure; TACS, thoracic aorta calcium score.
Change in Systolic Blood Pressure and Pulse Pressure According to Quartiles of TACS
| Variable | TACS Quartiles |
| ||||||
|---|---|---|---|---|---|---|---|---|
| 1st | 2nd | 3rd | 4th |
| 1st vs 2nd | 1st vs 3rd | 1st vs 4th | |
| ΔSBP | ||||||||
| Stage 1 | 12.9±21.4 | 11.2±20.4 | 14.0±24.7 | 12.4±21.5 | 0.864 | 0.864 | 0.644 | 0.824 |
| Stage 2 | 24.3±22.4 | 24.3±23.8 | 26.2±25.9 | 30.8±25.0 | 0.101 | 0.987 | 0.471 | 0.011 |
| Peak exercise | 51.2±21.6 | 52.1±24.1 | 52.2±22.0 | 56.8±21.7 | 0.027 | 0.713 | 0.677 | 0.017 |
| Recovery | 20.5±20.8 | 23.5±20.4 | 21.7±20.2 | 26.0±20.8 | 0.039 | 0.183 | 0.595 | 0.016 |
| ΔPP | ||||||||
| Stage 1 | 18.4±21.3 | 17.3±19.6 | 18.3±23.9 | 18.7±22.3 | 0.809 | 0.603 | 0.948 | 0.908 |
| Stage 2 | 30.7±21.6 | 29.3±20.4 | 30.2±23.8 | 37.4±25.8 | 0.013 | 0.546 | 0.859 | 0.012 |
| Peak exercise | 50.6±20.9 | 51.1±22.7 | 50.1±23.0 | 58.0±22.9 | 0.006 | 0.838 | 0.813 | 0.002 |
| Recovery | 22.0±19.2 | 24.4±19.7 | 22.5±19.2 | 28.7±20.2 | 0.008 | 0.244 | 0.813 | 0.002 |
ΔPP indicates change in pulse pressure during exercise; ΔSBP, change in systolic blood pressure during exercise; TACS, thoracic aorta calcium score.
Relationship of Standard Risk Factors and Aortic Calcification to Resting and Change in Systolic Blood Pressure During Exercise
| Variable | Resting SBP | ΔSBPstage2 | ΔSBPpeak | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| β |
| β |
| β |
| β |
| β |
| β |
| |
| Male sex | 0.042 | 0.270 | 0.044 | 0.321 | −0.139 | <0.001 | −0.092 | 0.043 | 0.150 | <0.001 | 0.149 | 0.001 |
| Age | 0.097 | 0.011 | 0.041 | 0.403 | −0.032 | 0.423 | −0.124 | 0.009 | −0.077 | 0.042 | −0.085 | 0.070 |
| Resting SBP | — | — | — | — | −0.071 | 0.070 | −0.044 | 0.401 | −0.151 | <0.001 | −0.165 | 0.001 |
| Resting DBP | — | — | — | — | −0.114 | 0.004 | −0.096 | 0.056 | −0.104 | 0.006 | −0.041 | 0.417 |
| Resting heart rate | 0.203 | <0.001 | 0.193 | <0.001 | 0.024 | 0.606 | 0.010 | 0.821 | −0.029 | 0.514 | 0.027 | 0.548 |
| Diabetes | 0.079 | 0.038 | 0.011 | 0.869 | 0.037 | 0.352 | — | — | 0.085 | 0.025 | 0.113 | 0.013 |
| Hypertension | 0.091 | 0.017 | 0.058 | 0.207 | 0.079 | 0.047 | 0.115 | 0.012 | 0.031 | 0.415 | — | — |
| Dyslipidemia | −0.008 | 0.839 | 0.002 | — | −0.024 | 0.550 | — | — | −0.084 | 0.027 | −0.048 | 0.283 |
| Use of BB | −0.007 | 0.865 | — | — | −0.091 | 0.020 | −0.113 | 0.012 | −0.002 | 0.950 | — | — |
| Use of CCB | −0.012 | 0.747 | — | — | 0.053 | 0.272 | — | — | −0.018 | 0.641 | — | — |
| Use of ACEi/ARB | 0.084 | 0.033 | 0.033 | 0.479 | 0.035 | 0.377 | — | — | 0.005 | 0.905 | — | — |
| BMI | 0.013 | 0.738 | — | — | 0.060 | 0.128 | — | — | 0.050 | 0.190 | 0.049 | 0.266 |
| Smoking | −0.034 | 0.365 | — | — | 0.040 | 0.312 | — | — | 0.045 | 0.240 | — | — |
| Total cholesterol/HDL | 0.055 | 0.188 | — | — | 0.034 | 0.435 | — | — | −0.035 | 0.402 | — | — |
| log(CACS+1) | 0.110 | 0.004 | 0.074 | 0.138 | −0.002 | 0.954 | −0.077 | 0.126 | 0.020 | 0.595 | −0.084 | 0.087 |
| log(TACS+1) | 0.149 | <0.001 | 0.096 | 0.048 | 0.132 | 0.001 | 0.175 | 0.001 | 0.071 | 0.060 | 0.100 | 0.010 |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta‐blocker; BMI, body mass index; CACS, coronary artery calcium score; CCB, calcium‐channel blocker; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; SBP, systolic blood pressure; TACS, thoracic aorta calcium score; ΔSBPpeak, change of systolic blood pressure during peak exercise; ΔSBPstage2, change of systolic blood pressure during stage 2 exercise.
Relationship of Standard Risk Factors and Aortic Calcification to Resting and Change in Pulse Pressure During Exercise
| Variable | Resting PP | ΔPPstage2 | ΔPPpeak | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| β |
| β |
| β |
| β |
| β |
| β |
| |
| Male sex | 0.011 | 0.771 | 0.021 | 0.643 | −0.086 | 0.030 | −0.125 | 0.060 | 0.098 | 0.010 | 0.056 | 0.217 |
| Age | 0.151 | <0.001 | 0.079 | 0.087 | −0.027 | 0.492 | −0.081 | 0.094 | −0.066 | 0.085 | −0.065 | 0.175 |
| Resting PP | — | — | — | — | −0.033 | 0.411 | — | — | −0.110 | 0.004 | −0.121 | 0.010 |
| Resting heart rate | 0.152 | 0.001 | 0.135 | 0.003 | 0.028 | 0.553 | −0.003 | 0.952 | −0.005 | 0.914 | 0.007 | 0.877 |
| Diabetes | 0.157 | <0.001 | 0.102 | 0.023 | 0.076 | 0.056 | 0.080 | 0.088 | 0.117 | 0.002 | 0.138 | 0.003 |
| Hypertension | 0.061 | 0.112 | — | — | 0.042 | 0.300 | — | — | 0.018 | 0.647 | — | — |
| Dyslipidemia | 0.021 | 0.579 | — | — | −0.050 | 0.209 | — | — | −0.069 | 0.072 | −0.021 | 0.642 |
| Use of BB | −0.035 | 0.363 | — | — | −0.085 | 0.038 | −0.121 | 0.009 | −0.022 | 0.570 | — | — |
| Use of CCB | 0.012 | 0.753 | — | — | 0.032 | 0.426 | — | — | −0.019 | 0.621 | — | — |
| Use of ACEi/ARB | 0.098 | 0.011 | 0.038 | 0.393 | 0.044 | 0.274 | — | — | 0.041 | 0.290 | — | — |
| BMI | 0.003 | 0.942 | — | — | 0.074 | 0.063 | 0.125 | 0.007 | 0.053 | 0.164 | 0.047 | 0.304 |
| Smoking | −0.035 | 0.351 | — | — | 0.024 | 0.541 | — | — | 0.033 | 0.391 | — | — |
| Total cholesterol/HDL | 0.046 | 0.265 | — | — | 0.002 | 0.959 | — | — | −0.045 | 0.280 | — | — |
| log(CACS+1) | 0.108 | 0.005 | 0.070 | 0.153 | 0.034 | 0.397 | −0.030 | 0.566 | 0.018 | 0.640 | −0.101 | 0.055 |
| log(TACS+1) | 0.173 | <0.001 | 0.097 | 0.049 | 0.105 | 0.008 | 0.128 | 0.004 | 0.086 | 0.023 | 0.144 | 0.004 |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta‐blocker; BMI, body mass index; CACS, coronary artery calcium score; CCB, calcium‐channel blocker; HDL, high‐density lipoprotein; PP, pulse pressure; TACS, thoracic aorta calcium score; ΔPPpeak, change of pulse pressure during peak exercise; ΔPPstage2, change of pulse pressure during stage 2 exercise.
Cox Proportional Hazards Regression for Predictors of Outcomes
| Outcome | Predictor | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| ||
| All events | Age | 1.14 (1.08–1.22) | <0.001 | 1.12 (1.05–1.19) | <0.001 |
| Male sex | 1.20 (0.72–2.01) | 0.488 | 1.06 (0.62–1.81) | 0.826 | |
| Hypertension | 1.15 (0.68–0.95) | 0.603 | — | — | |
| Diabetes | 0.82 (0.41–1.61) | 0.557 | — | — | |
| Dyslipidemia | 1.60 (0.95–2.70) | 0.081 | 1.96 (1.14–3.37) | 0.015 | |
| Resting heart rate | 1.01 (0.97–1.05) | 0.722 | — | ||
| BMI | 0.97 (0.88–1.06) | 0.461 | — | ||
| Smoking | 1.19 (0.58–2.42) | 0.635 | — | ||
| CACS ≥400 mm3 | 2.26 (0.97–5.27) | 0.059 | 1.83 (0.75–4.48) | 0.184 | |
| TACS 4th vs 1st to 3rd quartiles | 2.41 (1.44–4.04) | 0.001 | 1.24 (1.03–1.49) | 0.024 | |
| All‐cause death | Age | 1.27 (1.12–1.44) | <0.001 | 1.26 (1.09–1.46) | 0.002 |
| Male sex | 1.08 (0.33–3.53) | 0.904 | 0.77 (0.22–2.78) | 0.694 | |
| Hypertension | 1.02 (0.31–3.33) | 0.980 | — | — | |
| Diabetes | 0.38 (0.05–2.99) | 0.360 | — | — | |
| Dyslipidemia | 0.96 (0.29–3.16) | 0.949 | — | — | |
| Resting heart rate | 0.93 (0.83–0.13) | 0.155 | 0.96 (0.85–1.08) | 0.468 | |
| BMI | 0.69 (0.55–0.86) | 0.001 | 0.66 (0.50–0.87) | 0.003 | |
| Smoking | 0.66 (0.08–5.16) | 0.692 | — | — | |
| CACS ≥400 mm3 | 0.99 (0.21–4.59) | 0.991 | 0.47 (0.65–1.74) | 0.814 | |
| TACS 4th vs 1st to 3rd quartiles | 1.67 (0.49–5.72) | 0.412 | 0.93 (0.25–3.49) | 0.908 | |
| Heart failure | Age | 1.16 (1.02–1.32) | 0.029 | 1.08 (0.88–1.33) | 0.483 |
| Male sex | 1.71 (0.54–5.40) | 0.360 | 1.89 (0.33–10.69) | 0.473 | |
| Hypertension | 0.61 (0.19–1.91) | 0.392 | — | — | |
| Diabetes | 1.34 (0.36–4.94) | 0.665 | — | — | |
| Dyslipidemia | 2.32 (0.70–7.72) | 0.170 | 3.63 (0.62–21.28) | 0.152 | |
| Resting heart rate | 1.04 (0.99–1.09) | 0.155 | 1.03 (0.15–7.25) | 0.957 | |
| BMI | 0.98 (0.80–1.20) | 0.848 | — | — | |
| Smoking | 2.18 (0.59–8.04) | 0.244 | — | — | |
| CACS ≥400 mm3 | 1.80 (0.23–13.96) | 0.574 | 1.06 (0.15–7.25) | 0.957 | |
| TACS 4th vs 1st to 3rd quartiles | 3.20 (1.03–9.93) | 0.044 | 4.13 (0.69–24.62) | 0.119 | |
| Obstructive CAD | Age | 1.06 (0.91–1.23) | 0.450 | 1.03 (0.88–1.21) | 0.707 |
| Male sex | 1.56 (0.48–5.13) | 0.460 | 0.04 (0.29–3.77) | 0.956 | |
| Hypertension | 0.69 (0.21–2.26) | 0.537 | — | — | |
| Diabetes | 2.31 (0.68–7.89) | 0.183 | 0.58 (0.17–1.94) | 0.373 | |
| Dyslipidemia | 1.29 (0.39–4.22) | 0.678 | — | — | |
| Resting heart rate | 0.99 (0.89–1.10) | 0.825 | — | — | |
| BMI | 1.02 (0.83–1.26) | 0.826 | — | — | |
| Smoking | 1.40 (0.32–6.48) | 0.667 | — | — | |
| CACS ≥400 mm3 | 7.12 (1.89–26.87) | 0.004 | 7.04 (1.58–31.36) | 0.010 | |
| TACS 4th vs 1st to 3rd quartiles | 1.67 (0.49–5.70) | 0.414 | 1.45 (0.39–5.39) | 0.583 | |
| Stroke | Age | 1.12 (1.02–1.23) | 0.014 | 1.10 (0.99–1.22) | 0.076 |
| Male sex | 0.935 (0.42–2.17) | 0.871 | 0.80 (0.34–1.89) | 0.613 | |
| Hypertension | 2.35 (0.93–5.97) | 0.072 | 0.33 (0.76–5.04) | 0.139 | |
| Diabetes | 0.35 (0.08–1.49) | 0.155 | 1.96 (0.76–5.04) | 0.163 | |
| Dyslipidemia | 1.87 (0.82–4.30) | 0.139 | 1.83 (0.77–4.37) | 0.171 | |
| Resting heart rate | 1.02 (0.97–1.07) | 0.402 | — | — | |
| BMI | 1.07 (0.94–1.23) | 0.312 | — | — | |
| Smoking | 0.92 (0.28–3.10) | 0.896 | — | — | |
| CACS ≥400 mm3 | 1.733 (0.41–7.38) | 0.457 | 1.89 (0.42–8.56) | 0.410 | |
| TACS 4th vs 1st to 3rd quartiles | 2.89 (1.30–6.42) | 0.009 | 2.15 (1.09–5.13) | 0.044 | |
BMI indicates body mass index; CACS, coronary artery calcium score; CAD, coronary artery disease; CI, confidential interval; HDL, high‐density lipoprotein; HR, hazard ratio; TACS, thoracic aorta calcium score.
Figure 1Kaplan–Meier curves displaying the differences in all event‐free survival rates according to thoracic aorta calcium score quartiles.
Figure 2Kaplan–Meier curves displaying the differences in (A) stroke rates and (B) obstructive coronary artery disease according to quartiles of thoracic aorta calcium score (TACS) or coronary artery calcium score (CACS).